

Table S1. Ventricular arrhythmia events of patients treated with sacubitril/valsartan over 12 months.

Variables	Before Sacubitril/Valsartan <i>n</i> = 59	After Sacubitril/Valsartan <i>n</i> = 59	<i>p</i> Value *
Arrhythmias, n (%)			
Composite of VT, nsVT and VF	9 (15)	18 (30.5)	0.01
After 6 months	9 (15)	8 (8.42)	0.78
After 8 months	9 (15)	12 (20.3)	0.32
After 12 months	9 (15)	17 (28.8)	0.03
Ventricular fibrillation			
After 6 months	1 (1.7)	3 (5.08)	0.32
After 8 months	1 (1.7)	4 (6.78)	0.18
After 12 months	1 (1.7)	5 (8.47)	0.10
nsVT			
After 6 months	4 (6.78)	5 (8.47)	0.71
After 8 months	4 (6.78)	10 (16.9)	0.03
After 12 months	4 (6.78)	14 (23.7)	0.0039
Ventricular tachycardia			
After 6 months	4 (6.78)	3 (5.08)	0.65
After 8 months	4 (6.78)	6 (10.2)	0.48
After 12 months	4 (6.78)	8 (8.42)	0.21
Rhythm therapy (ATP; Shock); n (%)			
After 6 months	4 (6.78)	5 (8.47)	1.00
After 8 months	4 (6.78)	8 (13.6)	0.34
After 12 months	4 (6.78)	10 (16.9)	0.15

* *p* values for the comparison before and after sacubitril/valsartan, VT = ventricular tachycardia, nsVT = non-sustained ventricular tachycardia, VF = ventricular fibrillation, ATP = antitachycardia pacing.

Table S2. Comparison of life-threatening arrhythmia events in presence or absence of ischemic cardiomyopathy.

Variables	Before Sacubitril/Valsartan <i>n</i> = 59	After Sacubitril/Valsartan <i>n</i> = 59	<i>p</i> Value *
Ischemic cardiomyopathy; <i>n</i> = 30			
Malignant Arrhythmia (VF, nsVT, VT) <i>n</i> (%)			
After 6 months	5/30 (16.6)	6/30 (20.0)	1.00
After 8 months	5/30 (16.6)	7/30 (23.3)	0.73
After 12 months	5/30 (16.6)	12/30 (40.0)	0.09
Ventricular fibrillation <i>n</i> (%)			
After 6 months	0/30 (0)	3/30 (10.0)	0.25
After 8 months	0/30 (0)	3/30 (10.0)	0.25
After 12 months	0/30 (0)	4/30 (13.3)	0.13
nsVT <i>n</i> (%)			
After 6 months	3/27 (11.1)	4/27 (14.8)	1.00
After 8 months	3/27 (11.1)	6/27 (22.2)	0.38

After 12 months	3/27 (11.1)	10/27 (37.0)	0.04
Ventricular tachycardia <i>n</i> (%)			
After 6 months	2/30 (6.67)	2/30 (6.67)	1.00
After 8 months	2/30 (6.67)	3/30 (10.0)	1.00
After 12 months	2/30 (6.67)	5/30 (16.7)	0.45
Non-Ischemic cardiomyopathy; <i>n</i> = 29			
Malignant arrhythmia (VF, nsVT, VT) <i>n</i> (%)			
After 6 months	4/29 (13.8)	2/29 (6.90)	0.63
After 8 months	4/29 (13.8)	5/29 (17.2)	1.00
After 12 months	4/29 (13.8)	5/29 (17.2)	1.00
Ventricular fibrillation <i>n</i> (%)			
After 6 months	1/29 (3.45)	0/29 (0.00)	1.00
After 8 months	1/29 (3.45)	1/29 (3.45)	1.00
After 12 months	1/29 (3.45)	1/29 (3.45)	1.00
nsVT <i>n</i> (%)			
After 6 months	1/17 (5.88)	1/17 (5.88)	1.00
After 8 months	1/17 (5.88)	4/17 (23.5)	0.25
After 12 months	1/17 (5.88)	4/17 (23.5)	0.25
Ventricular tachycardia <i>n</i> (%)			
After 6 months	2/29 (6.90)	1/29 (3.45)	1.00
After 8 months	2/29 (6.90)	3/29 (10.3)	1.00
After 12 months	2/29 (6.90)	3/29 (10.3)	1.00

* *p* values for the comparison before and after sacubitril/valsartan. VT = ventricular tachycardia, nsVT = non-sustained ventricular tachycardia, VF = ventricular fibrillation.